+1 - Solvay

Pharmaceuticals Sector
Results
in 2007
Gerda Greeve
Microbiological analyst
In 2007, Solvay Pharmaceuticals
sales amounted to EUR 2.6 billion,
on a par with those of the record
year 2006. This represents growth
of + 3% on a constant exchange
rate basis. Earnings and margins
are also comparable to those
of 2006.
In 2007 we achieved records in
two fields:
• sales of TRICOR ® in the USA,
where for the first time Abbott
posted sales in excess of
USD 1.2 billion, up 16% from
2006 and confirming this drug’s
“blockbuster” status;
• ANDROGEL ® sales which,
worldwide, grew by 12% to above
EUR 300 million for the first time.
Distribution by geographic zones
shows the USA to be our largest
market, with 37% of sales in EUR.
Sales here grew by 6% in 2007,
expressed in EUR (16% in USD),
compared with 2006.
Pharmaceuticals
23
Sales in the US passed the
EUR 900 million mark for the
first time.
The European Union comes in third
place with 28%, now behind the
rest of the world, in second place
with 35% of total sales.
Russia today is our third largest
single market after the USA and
France:
• United States: EUR 957 million,
37% of the total, in first position;
• France: EUR 189 million, 7% of
the total, in second position;
• Russia: EUR 130 million, 5% of
the total, in third position.
Solvay Global Annual Report 2007